Showing results (151-160 of 215) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progressionRobert Z Orlowski, Arnon Nagler, Pieter Sonneveld, et al.
Leukemia|May 24, 2020
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)Evangelos Terpos, Monika Engelhardt, Gordon Cook, et al.
European Journal of Haematology|October 11, 2024
Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow CytometryLudmila Muronova, Ondrej Soucek, David Zihala, et al.
Leukemia & Lymphoma|September 27, 2019
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general populationHeinz Ludwig, Wolfram Pönisch, Stefan Knop, et al.
Leukemia & Lymphoma|July 24, 2018
Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 casesArtur Jurczyszyn, Julio Davila, K Martin Kortüm, et al.
Plos One|April 16, 2015
Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathyJiri Minarik, Petr Pavlicek, Ludek Pour, et al.
British Journal of Haematology|April 7, 2017
Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II studyOrhan Sezer, Meral Beksac, Roman Hajek, et al.
Journal of Medical Economics|February 17, 2026
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myelomaMeletios A Dimopoulos, Mario Boccadoro, Hermann Einsele, et al.
Haematologica|June 22, 2019
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugsVittorio Montefusco, Francesca Gay, Stefano Spada, et al.
Blood|February 5, 2011
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Nikhil C Munshi, Kenneth C Anderson, P Leif Bergsagel, et al.
Pageof 22